• Simplify 340B with Dashboard Analytics

    Our powerful analytics platform provides users with robust and insightful visibility into their 340B program. With an intuitive, cloud-based platform, an advanced reporting machine, and reliable analytics, RxStrategies’ Dashboard Analytics solution simplifies your entire 340B program. Real-time accumulator views, WAC-spend analyses, robust drill-down capabilities, and custom report creations provide our users access to the exact… Read more »

  • The Future of Policy at NACHC 2019

      March 27 – 30, RxStrategies representatives Rhodie Smith and Justin Rolling will attend the 2019 Policy and Issues Forum hosted by the National Association of Community Health Centers (NACHC). As one of the largest conferences on health policy, people from all corners of the administration and operations of health care will attend. The priorities… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Clinical Insights: May 9, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Plenvu® (polyethylene glycol 3350 with electrolytes) – May 7, 2018 – Salix Pharmaceuticals, Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Plenvu®… Read more »

  • Clinical Insights: April 3, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval SymfiTM (efavirenz, lamivudine and tenofovir disoproxil fumarate) – March 22, 2018 – Mylan N.V. announced that it will introduce in the U.S. a third cost-saving HIV… Read more »

  • Clinical Insights: March 23, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval IlumyaTM (tildrakizumab-asmn) – New Drug Approval – March 21, 2018 – Sun Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved… Read more »

  • Clinical Insights: October 10, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Zilretta™ (triamcinolone acetonide extended-release) – October 6, 2017 – Flexion Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release… Read more »

  • Clinical Insights: September 15, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Aliqopa™ (copanlisib) – September 14, 2017 – The U.S. Food and Drug Administration granted accelerated approval to Aliqopa™ (copanlisib) for the treatment of adults with relapsed… Read more »